Lynwood Capital Management Inc. 13D and 13G filings for BriaCell Therapeutics Corp.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-02-14 4:35 pm Purchase |
2022-12-31 | 13G | BriaCell Therapeutics Corp. BCTX |
Lynwood Capital Management Inc. | 97,333 9.300% |
39,333 (+67.82%) |
Filing |
| 2022-08-01 07:00 am Purchase |
2022-07-20 | 13G | BriaCell Therapeutics Corp. BCTX |
Lynwood Capital Management Inc. | 58,000 5.600% |
5,667 (+10.83%) |
Filing |
| 2022-02-11 08:00 am Sale |
2021-12-31 | 13G | BriaCell Therapeutics Corp. BCTX |
Lynwood Capital Management Inc. | 52,333 4.920% |
-6,333 (-10.80%) |
Filing |
| 2021-08-17 4:04 pm Purchase |
2021-08-09 | 13G | BriaCell Therapeutics Corp. BCTX |
Lynwood Capital Management Inc. | 58,667 5.800% |
58,667 (New Position) |
Filing |